Quoted from http://www.reuters.com/article/marketsNews/idINN1943894220090619?rpc=44
US FDA staff urge review of Abbott drug risks
Fri Jun 19, 2009 11:21am EDT
By Lisa Richwine
WASHINGTON, June 19 (Reuters) - U.S. drug reviewers have recommended additional study of delayed development reported in children of mothers who took Abbott Laboratories' (ABT.N) anti-seizure drug Depakote.
Six cases received since its approval in 1983, including two siblings reported to have autism, "raise concerns," Food and Drug Administration staff wrote in a May 6 memo released on Friday.
Limitations in the reports "make it impossible to definitively conclude" the drug played a role, and genetics or other factors may have contributed, especially in the two sibling cases of autism, the FDA reviewers said.